Ramnika I. Gumber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ramnika I. Gumber has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Cecilia C. Low Wang
University of Colorado Anschutz Medical Campus
1 shared publication - Daniel C. Brennan
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
1 shared publication - Jeong Mi Park
Department of Pharmacy Michigan Medicine Ann Arbor Michigan USA
1 shared publication - Krysta Walter
Department of Pharmacy, University of Michigan, Ann Arbor, MI, USA
1 shared publication - Maria Papaleontiou
Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, North Campus Research Complex, 2800 Plymouth Road, Bldg. 16, Rm G024W, Ann Arbor, MI 48109
1 shared publication - Palak Choksi
Department of Medicine, Division of Endocrinology, Metabolism and Diabetes University of Colorado Aurora Colorado USA
1 shared publication
Latest Publications
- Open Access
- 11 December 2024
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (2) , 82-90
Prescribing practices and barriers to use of sodium‐glucose cotransporter 2 inhibitors and glucagon‐like Peptide‐1 receptor agonists in adult kidney transplant recipients: A survey of endocrinology and nephrology prescribers
Clinical practice variability exists regarding the use of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) in kidney transplant recipients (KTRs). The objective of this study was to understand prescribing practices and barriers for the use of SGLT2i and GLP‐1RA among endocrinology and nephrology prescribers caring for KTRs. A 19‐item electronic survey assessing prescribing practices and barriers for the use of SGLT2i and GLP‐1RA in adult KTRs was distributed to all members of the Planning Research in Inpatient Diabetes/Planning Research in Outpatient Diabetes (PRIDE/PROUD) group and the American Society of Transplantation Kidney Pancreas Community of Practice via email listservs between July and November 2023. Endocrinology and nephrology prescribers caring for adult KTRs with type 2 diabetes mellitus (T2DM) or post‐transplant diabetes mellitus (PTDM) were eligible. A total of 50 responses were included for analysis ( n = 25 endocrinology, n = 25 nephrology). Respondents prescribed SGLT2i and GLP‐1RA to adult KTRs with T2DM/PTDM with the following frequency: always (4% SGLT2i, 6% GLP‐1RA), often (34% SGLT2i, 30% GLP‐1RA), sometimes (34% SGLT2i, 36% GLP‐1RA), rarely (22% SGLT2i, 20% GLP‐1RA), or never (6% SGLT2i, 8% GLP‐1RA). The most common indication for both drug classes was diabetes mellitus (DM)/hyperglycemia (84% SGLT2i, 90% GLP‐1RA). Most prescribers felt comfortable initiating a SGLT2i (58%) or GLP‐1RA (62%) between 1 and 6 months post‐transplant. Prescribers were always or often concerned about infection (67%) with the use of SGLT2i and gastrointestinal intolerance (66%) with GLP‐1RA. Cost of treatment/insurance coverage/need for prior authorization and patient concern for drug cost was identified as being very likely or likely barriers for prescribing these drug classes post‐transplant (54% SGLT2i, 62% GLP‐1RA). SGLT2i and GLP‐1RA are prescribed mainly for DM/hyperglycemia by endocrinology and nephrology prescribers between 1 and 6 months postkidney transplant. Concerns surrounding medication access and cost were the most frequently reported barriers to use.
- 11 December 2024
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (2) , 82-90
Open AccessPrescribing practices and barriers to use of sodium‐glucose cotransporter 2 inhibitors and glucagon‐like Peptide‐1 receptor agonists in adult kidney transplant recipients: A survey of endocrinology and nephrology prescribers
Clinical practice variability exists regarding the use of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) in kidney transplant recipients (KTRs). The objective of this study was to understand prescribing practices and barriers for the use of SGLT2i and GLP‐1RA among endocrinology and nephrology prescribers caring for KTRs. A 19‐item electronic survey assessing prescribing practices and barriers for the use of SGLT2i and GLP‐1RA in adult KTRs was distributed to all members of the Planning Research in Inpatient Diabetes/Planning Research in Outpatient Diabetes (PRIDE/PROUD) group and the American Society of Transplantation Kidney Pancreas Community of Practice via email listservs between July and November 2023. Endocrinology and nephrology prescribers caring for adult KTRs with type 2 diabetes mellitus (T2DM) or post‐transplant diabetes mellitus (PTDM) were eligible. A total of 50 responses were included for analysis ( n = 25 endocrinology, n = 25 nephrology). Respondents prescribed SGLT2i and GLP‐1RA to adult KTRs with T2DM/PTDM with the following frequency: always (4% SGLT2i, 6% GLP‐1RA), often (34% SGLT2i, 30% GLP‐1RA), sometimes (34% SGLT2i, 36% GLP‐1RA), rarely (22% SGLT2i, 20% GLP‐1RA), or never (6% SGLT2i, 8% GLP‐1RA). The most common indication for both drug classes was diabetes mellitus (DM)/hyperglycemia (84% SGLT2i, 90% GLP‐1RA). Most prescribers felt comfortable initiating a SGLT2i (58%) or GLP‐1RA (62%) between 1 and 6 months post‐transplant. Prescribers were always or often concerned about infection (67%) with the use of SGLT2i and gastrointestinal intolerance (66%) with GLP‐1RA. Cost of treatment/insurance coverage/need for prior authorization and patient concern for drug cost was identified as being very likely or likely barriers for prescribing these drug classes post‐transplant (54% SGLT2i, 62% GLP‐1RA). SGLT2i and GLP‐1RA are prescribed mainly for DM/hyperglycemia by endocrinology and nephrology prescribers between 1 and 6 months postkidney transplant. Concerns surrounding medication access and cost were the most frequently reported barriers to use.
- 20 May 2021
- Published by Wiley in Pediatric Transplantation
- Vol. 25 (6) , e14032
Book review: Post‐transplant lymphoproliferative disorders. Second edition. Edited by Vikas R. Dharnidharka, Michael Green, Steven A. Webber and Ralf Ulrich Trappe
- 20 May 2021
- Published by Wiley in Pediatric Transplantation
- Vol. 25 (6) , e14032
Book review: Post‐transplant lymphoproliferative disorders. Second edition. Edited by Vikas R. Dharnidharka, Michael Green, Steven A. Webber and Ralf Ulrich Trappe